Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities

doi:10.4240/wjgs.v16.i6.1513

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (85)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=83

Jun 27, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Surg. Jun 27, 2024; 16(6): 1513-1516
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1513

Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities

Murat Bardakçi, Yakup Ergun

Murat Bardakçi, Department of Medical Oncology, Diyarbakır Gazi Yasargil Training and Research Hospital, Diyarbakir 021000, Kayapinar, Türkiye

Yakup Ergun, Department of Medical Oncology, Antalya City Hospital, Antalya 07080, Türkiye

Author contributions: Bardakci M reviewed the literature and wrote the manuscript; Ergun Y contributed to the discussion and design of the manuscript; all authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Conflict-of-interest statement: The author(s) declare that there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Yakup Ergun, MD, Department of Medical Oncology, Antalya City Hospital, Gocerler Neighborhood, 5379 Street, Antalya 07080, Türkiye. dr.yakupergun@gmail.com

Received: February 26, 2024
Revised: April 29, 2024
Accepted: May 17, 2024
Published online: June 27, 2024
Processing time: 124 Days and 14.3 Hours

Core Tip

Core Tip: In the context of gastric cancer patients with liver metastases, the standard treatment often involves combinations of immunotherapy and chemotherapy, particularly in specific patient groups. However, considering the intricate dynamics of the tumor microenvironment, the effectiveness of immunotherapies may be limited in cases of liver metastatic disease. In this context, especially considering the potential benefits of locally targeted treatments to the liver, further research and clinical studies are necessary to expand effective therapeutic options.